Back to top

View the PFP Archive

Stocks closed lower yesterday. Not by much, but lower nonetheless.
Kevin Matras   
Profit from the Pros
By Kevin Matras
Executive Vice President
Zacks Investment Research
  

Stocks Closed Lower Yesterday, Employment Report Beats Expectations

Stocks closed lower yesterday. Not by much, but lower nonetheless.

Stocks opened strongly on a better-than-expected jobs report. But by mid-morning, the gains were gone.

The indexes flitted between positive and negative territory for most of the afternoon before settling slightly in the red by the close.

Yesterday's Employment Situation report came in much better than expected with 130,000 new jobs being created in January (172,000 in the private sector and -42,000 in the public), vs. the consensus for 70,000 (75K private and -5K public).

The unemployment rate eased to 4.3% vs. last month's 4.4% and views for the same. The participation rate rose to 62.5% from 62.4%. Average hourly wages were up 0.4% m/m vs. last month's downwardly revised 0.1% (from 0.3%), and estimates for 0.3%. The y/y change was at 3.7%, up a bit vs. the consensus of 3.6%, but down from last month's 3.8% pace.

The industries with the biggest job gains were Health Care, which added 82,000 jobs; Social Assistance jobs were up 42,000; and Construction was up 33,000.

Revisions from previous month's saw November shed -15,000 jobs to 41K, and December lessen by -2,000 to 48K.

All in all, it was a solid report. And it underscored the resilience of the economy. While job gains were clustered in just a few industries, most of the other industries were essentially flat. And flat is better than down. As for the sharp government reductions, much of that much was a result of deferred resignation offers from 2025 that finally came off federal payrolls last month.

The only downside to the stronger report was calling into question the timing of the next rate cut. With inflation easing and the labor market stabilizing (even strengthening), there's an argument to be made that there's no rush to cut.

Although, the odds even prior to yesterday's jobs report, favored a cut in June rather than March or April. (Fed Chair Jerome Powell's term ends in in May. And the new nominee, Kevin Warsh, is expected to push for cuts in the first month he's at the helm.)

Earnings season continues. Before the open yesterday, Vertiv posted a positive EPS surprise of 5.43%, and a positive sales surprise of 0.07%. That translated to a quarterly EPS growth rate of 37.4% vs. this time last year, and a sales growth of 22.7%. Increased data center demand sent backlog orders surging to $15 billion, up more than 100% vs. last year. And they see strong pipeline growth. Shares soared by 24.5% yesterday, hitting new all-time highs in the process.

After the close, AppLovin posted a positive EPS surprise of 12.1%, and a positive sales surprise of 2.88%. That equated to a quarterly EPS growth rate of 87.3%, and a sales growth of 21.2%. They also upped their revenue guidance for next quarter by 3% above expectations. But they've struggled lately, after putting in a spectacular performance last year of 108%. Nevertheless, they were down -3.41% in the regular session, and another -7% in after-hours trade.

Today we'll hear from another 280 companies set to report, including Anheuser-Busch InBev before the open, and Arista Networks and Applied Materials after the close.

On the economic report front today we'll get Weekly Jobless Claims, and Existing Home Sales.

And then tomorrow we'll get the Consumer Price Index (CPI) retail inflation report for January.

In the meantime, with 2 more days to go, the major indexes are mostly up for the week. And with a little bit of cooperation, they may all be.

See you tomorrow,

Kevin Matras

Executive Vice President, Zacks Investment Research

Sponsor

Florida Is Testing New Alternative Pesticide

Med-X is moving toward a possible Nasdaq listing (ticker: MXRX) – and once that happens, the early window closes.

Before Wall Street prices it in, Med-X has already generated $6.4M in sales, placed Nature-Cide on Amazon.com, Walmart.com, and Kroger.com, and begun expanding into 41+ global markets.

Florida's mosquito control districts–America's most well-funded and influential–are independently testing Nature-Cide botanical pesticides, as Med-X pursues WHO pre-qualification for global public health adoption.

This is the gap before the bell.

Review the Med-X opportunity now – before Nasdaq plans unfold.


Disclosures: This is a paid advertisement for Med-X's Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com

Most Popular Articles from Zacks.com

Image: Bigstock

These 3 Companies Shattered Quarterly Records

The 2025 Q4 earnings season continues to be one of positivity, with AAPL, ETN and SOFI posting record-breaking results. Read More »

Image: Bigstock

3 HCM Stocks to Consider After January's Strong U.S. Jobs Report

Human Capital Management stocks ADP, WDAY and PCTY are starting to make an argument for being in oversold territory following January's strong U.S. Jobs report. Read More »

Image: Bigstock

This AI Defense Stock Is One That Wall Street Can't Stop Buying

Palantir expects 2026 revenues to more than double from 2025 as AIP adoption and deal values accelerate. Read More »

Image: Shutterstock

Quantum Hype vs. Profits: Do NVDA and MSFT Have the Edge?

Analysts are increasingly recommending established tech companies with quantum divisions, like NVIDIA (NVDA) or Microsoft (MSFT), as less risky ways to capture quantum upside. Read More »

Image: Bigstock

Amazon Bets Big on AI With $200B Capex: Buy, Sell or Hold the Stock?

Amazon's $200 billion capex plan introduces meaningful near-term uncertainty, particularly around free cash flow and margin pressure from satellite investments and international expansion. Read More »

Sponsor

Get Your Free Copy of Finding #1 Stocks - A $49.95 Value

Starting today, you can claim a free copy of Finding #1 Stocks by Zacks' EVP Kevin Matras. You don't even have to pay for shipping! Its 300 pages unfold virtually every trading secret he has learned over the last 25 years to beat the market. Here's what's inside:

  • See the exact formulas of strategies that produced gains up to +98.6% in 2025 - more than 5X the market's +17.5%.
  • How to spot bullish set-ups and bearish break-downs to stay ahead of the market…
  • Traits to determine the type of trader you are and finding stocks with highest probability of success…
  • Kevin's personal all-time favorite screening strategy…
  • And much more!

This limited-time offer will end midnight Saturday, February 14 or when our inventory is depleted. Don't miss this unique opportunity.

Get your FREE book now »

Image: Shutterstock

Bull of the Day: Lumentum (LITE)

Stellar beat-and-raise quarter ignites shares to $600 as top & bottom growth estimates track +76% & +270%. Read More »

New Zacks Strong Buys for February 12th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today. Read More »

 

Download our app for convenient on-the-go access to even more—daily and weekly newsletters published by Zacks experts, proprietary research and tools, and Portfolio Tracker on Zacks.com.

Download our Zacks App for Apple iOS
Download our Zacks App for Android

Visit Success Stories to hear how Zacks research, tools and portfolios help our members outperform the market.